See more : B.O.S. Better Online Solutions Ltd. (BOSC) Income Statement Analysis – Financial Results
Complete financial analysis of Therma Bright Inc. (TBRIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Therma Bright Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Koyou Rentia Co., Ltd. (7081.T) Income Statement Analysis – Financial Results
- 6D Global Technologies, Inc. (SIXD) Income Statement Analysis – Financial Results
- Kyung Dong Navien Co., Ltd. (009450.KS) Income Statement Analysis – Financial Results
- Nomura Research Institute, Ltd. (4307.T) Income Statement Analysis – Financial Results
- Cashmere Valley Bank (CSHX) Income Statement Analysis – Financial Results
Therma Bright Inc. (TBRIF)
About Therma Bright Inc.
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 172.75K | 251.02K | 250.86K | 770.03K | 43.81K | 38.54K | 37.83K | 6.50K |
| Cost of Revenue | 614.00 | 0.00 | 75.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00K | 372.71K | 121.96K | 281.02K | 27.43K | 24.08K | 23.72K | 0.00 |
| Gross Profit | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.27K | 0.00 | 0.00 | 0.00 | 0.00 | 31.75K | -121.69K | 128.90K | 489.01K | 16.38K | 14.45K | 14.11K | 6.50K |
| Gross Profit Ratio | 97.64% | 100.00% | 45.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.31% | 0.00% | 0.00% | 0.00% | 0.00% | 18.38% | -48.48% | 51.38% | 63.50% | 37.38% | 37.50% | 37.30% | 100.00% |
| Research & Development | 9.69K | 446.58K | 805.54K | 1.37M | 13.08K | 60.67K | 92.49K | 97.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 570.00 | 9.05K | 58.65K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 0.00 | 0.00 | 756.94K | 0.00 | 0.00 | 0.00 | 0.00 | 704.05K | 706.22K | 26.73K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 68.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.04K | 0.00 | 0.00 | 0.00 | 0.00 | 2.12K | 23.22K | 115.00 |
| SG&A | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.10M | 1.30M | 1.22M | 1.96M | 1.15M | 706.17K | 729.44K | 26.84K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.16M | 3.63M | 5.90M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.11M | 1.32M | 1.31M | 2.10M | 1.18M | 713.41K | 931.71K | 28.10K |
| Cost & Expenses | 1.16M | 3.63M | 5.98M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 352.30K | 440.91K | 317.77K | 262.41K | 193.63K | 1.25M | 1.70M | 1.43M | 2.38M | 1.21M | 737.49K | 955.43K | 28.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 0.00 | 0.00 |
| Interest Expense | 8.60K | 13.44K | 1.38K | 0.00 | 17.40K | 18.91K | 8.74K | 0.00 | 0.00 | 3.90K | 643.97K | 550.99K | 473.02K | 423.68K | 312.72K | 267.74K | 0.00 | 0.00 | 0.00 | 1.27K | 0.00 | 0.00 |
| Depreciation & Amortization | 99.51K | 75.38K | 53.85K | 57.98K | 2.98K | 2.79K | 76.00 | 247.00 | 22.82K | 3.90K | 1.80M | 2.30M | 473.02K | 423.68K | 8.89K | 20.34K | 97.21K | 136.62K | 35.73K | 21.00K | 202.27K | 163.63K |
| EBITDA | -2.34M | -3.68M | -5.73M | -8.55M | -606.31K | -400.24K | -1.24M | -965.10K | -205.55K | -350.59K | 710.24K | 1.43M | -262.41K | -193.63K | -1.07M | -1.82M | -1.09M | -1.47M | -1.13M | -1.35M | -466.92K | -715.33K |
| EBITDA Ratio | -8,988.07% | -15,393.76% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,768.46% | -3,096.93% | -4,288.52% | -20,514.16% | 0.00% | 0.00% | 0.00% | 0.00% | -618.36% | -567.40% | -433.19% | -190.85% | -2,582.01% | -1,759.32% | -1,890.80% | 2,184.40% |
| Operating Income | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | -400.03K | -1.24M | -965.34K | -205.55K | -354.49K | -1.08M | -868.76K | -735.43K | -617.31K | -1.09M | -1.44M | -1.18M | -1.61M | -1.17M | -698.95K | -917.60K | -21.60K |
| Operating Income Ratio | -4,355.04% | -15,076.51% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,769.00% | -3,097.72% | -4,288.52% | -20,742.36% | 0.00% | 0.00% | 0.00% | 0.00% | -633.18% | -575.50% | -471.94% | -208.59% | -2,663.56% | -1,813.82% | -2,425.45% | -332.17% |
| Total Other Income/Expenses | -1.32M | -164.64K | -196.39K | -74.54K | -19.56K | -21.90K | -8.81K | -247.00 | -472.00 | -1.88K | 1.15M | 1.73M | -41.06K | 0.00 | -420.04K | -390.97K | -228.63K | -95.70K | 17.40K | -589.48K | 3.76K | -42.30K |
| Income Before Tax | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -1.84M | -1.41M | -1.70M | -1.15M | -1.96M | -959.90K | -21.65K |
| Income Before Tax Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -731.25% | -563.07% | -221.02% | -2,623.86% | -5,079.90% | -2,537.27% | -332.93% |
| Income Tax Expense | 0.00 | 0.00 | 1.38K | -178.58K | 17.40K | 18.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 312.72K | 267.74K | 195.65K | 133.18K | 20.67K | 361.30K | -295.99K | -9.50K |
| Net Income | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -2.10M | -1.61M | -1.84M | -1.15M | -2.32M | -663.91K | -12.15K |
| Net Income Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -837.92% | -641.07% | -238.31% | -2,623.86% | -6,017.49% | -1,754.88% | -186.82% |
| EPS | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
| Weighted Avg Shares Out (Dil) | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
Therma Bright's Distribution Partners Achieve 100% HCPCS Code Reimbursement In Under 60 Days
Distributors' medical partner networks impressed with Venowave device, speed of Medicare/Medicaid processing and prepare roadmaps to drive sales Toronto, Ontario--(Newsfile Corp. - December 5, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a...
Therma Bright to Spin Off Consumer Product Portfolio to Create Two Publicly Traded Companies
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, has completed its announced strategic review, and has set the course to...
Therma Bright Announces Shares for Debt Issuance
Toronto, Ontario--(Newsfile Corp. - November 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that the...
Therma Bright's Investment Partnership InStatin Joins Forces with InVixa to Enhance Its Patent Portfolio For The Development Of Innovative Respiratory Solutions
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung disease Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner...
Therma Bright Announces Shares for Debt Issuance
Toronto, Ontario--(Newsfile Corp. - October 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces...
Therma Bright Announces Quantify Medical as Nationwide U.S. Distribution Partner from August 22, 2024 Press Release
Quantify Medical Sees Initial Success with Venowave VW5 Sales and Medicare/Medicaid Reimbursement Test Therma Bright Closes First Tranche of Non-Brokered Concurrent Private Placement for CAD $174,900 Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB:...
Therma Bright Announces Non-Brokered LIFE Financing & Concurrent Private Placement for up to a combined CAD$6 Million
LIFE Financing and Concurrent Private Placement to Include Common Shares Only and no Warrants Toronto, Ontario--(Newsfile Corp. - September 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in...
Therma Bright Investment Portfolio Company InStatin Secures Mountain West Research Discovery Study Agreement
Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human Trials. Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"),...
Therma Bright Announces Shares for Debt Issuance to Include Portfolio Company AI4LYF & IR Agreement
Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that AI4LYF...
Therma Bright Welcomes Medical Device & Pharmaceutical Veteran Douglas S. Sommerville to Its Advisory Board
New Advisory Board Member will focus on Venowave sales and business development efforts Toronto, Ontario--(Newsfile Corp. - September 12, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic...
Source: https://incomestatements.info
Category: Stock Reports